Cerebrospinal fluid biomarkers and proximity to diagnosis in preclinical familial Alzheimer's disease.

Dementia and Geriatric Cognitive Disorders
John M RingmanGreg M Cole

Abstract

Biological markers of utility in tracking Alzheimer's disease (AD) during the presymptomatic prodromal phase are important for prevention studies. Changes in cerebrospinal fluid (CSF) levels of 42-amino-acid β-amyloid (Aβ(42)), total tau protein (t-tau) and phosphorylated tau at residue 181 (p-tau(181)) during this state are incompletely characterized. We measured CSF markers in 13 carriers of familial AD (FAD) mutations that are fully penetrant for causing AD (PSEN1 and APP) and in 5 non-mutation-carrying family members. Even among the entirely presymptomatic mutation carriers (n = 9), Aβ(42) was diminished (388.7 vs. 618.4 pg/ml, p = 0.004), and t-tau (138.5 vs. 50.5 pg/ml, p = 0.002) and p-tau(181) (71.7 vs. 24.6 pg/ml, p = 0.003) were elevated. There was a negative correlation between Aβ(42) levels and age relative to the family-specific age of dementia diagnosis. Our data are consistent with a decline in CSF Aβ(42) levels occurring at least 20 years prior to clinical dementia in FAD.

References

Nov 1, 1975·Journal of Psychiatric Research·M F FolsteinP R McHugh
Apr 4, 1998·Journal of Neurology, Neurosurgery, and Psychiatry·N AndreasenK Blennow
Sep 13, 2006·Archives of Neurology·Henrik ZetterbergAnders Wallin
Jun 8, 2007·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·William E KlunkSteven T DeKosky
Apr 1, 2008·Dementia and Geriatric Cognitive Disorders·John M RingmanRobert W Baloh
Jul 23, 2009·JAMA : the Journal of the American Medical Association·Niklas MattssonKaj Blennow
Feb 27, 2010·Annals of Neurology·John C MorrisMark A Mintun
Jan 8, 2011·Neuro-degenerative Diseases·Juan ForteaRaquel Sánchez-Valle
Jan 12, 2011·Archives of Neurology·Ozioma C OkonkwoUNKNOWN Alzheimer's Disease Neuroimaging Initiative
Mar 19, 2011·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·William Thies
Mar 19, 2011·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·UNKNOWN Alzheimer's Association
Jun 15, 2011·Archives of Neurology·Raymond Y LoUNKNOWN Alzheimer's Disease Neuroimaging Initiative
Sep 29, 2011·Dementia and Geriatric Cognitive Disorders·Liana G ApostolovaJohn M Ringman

❮ Previous
Next ❯

Citations

Apr 30, 2013·Biosensors & Bioelectronics·Paola GagniMarcella Chiari
Jun 12, 2013·Nature Reviews. Neurology·Jessica B LangbaumEric M Reiman
Jan 24, 2013·Dementia and Geriatric Cognitive Disorders Extra·John M RingmanCharles G Glabe
Jun 27, 2013·Molecular Neurodegeneration·Christoffer RosénHenrik Zetterberg
Aug 25, 2012·Biomarkers in Medicine·Henrik ZetterbergSanna-Kaisa Herukka
Aug 25, 2012·Biomarkers in Medicine·Henrik Zetterberg, Pieter Jelle Visser
Jan 1, 2015·Nature Reviews. Disease Primers·Colin L MastersJeffrey L Cummings
Nov 27, 2015·The Indian Journal of Medical Research·Neelum T AggarwalDavid A Bennett
Feb 18, 2015·Brain : a Journal of Neurology·John M RingmanUNKNOWN Dominantly Inherited Alzheimer Network
Aug 7, 2013·Scientific Reports·Koichi InoueToshimasa Toyo'oka
Jul 22, 2017·Neuroscience·Nadia El KadmiriSellama Nadifi
Oct 21, 2015·Journal of Alzheimer's Disease : JAD·Dipti Jigar ShahSteven W Graves
Sep 25, 2015·Journal of Alzheimer's Disease : JAD·Simone ListaHarald Hampel
May 6, 2014·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·Kaj BlennowHarald Hampel
Jul 16, 2013·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·Simone ListaHarald Hampel
Nov 20, 2012·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·Henrik Zetterberg, Kaj Blennow
Apr 5, 2018·Journal of Alzheimer's Disease : JAD·Steinunn Thordardottir, Caroline Graff
May 24, 2020·Diagnostics·Thuy Trang NguyenVan Giau Vo
Jun 20, 2020·Journal of Veterinary Internal Medicine·Ioanna StylianakiNikolaos G Papaioannou
Sep 29, 2020·Frontiers in Aging Neuroscience·Christiana BjorkliIoanna Sandvig
Nov 28, 2020·Parkinsonism & Related Disorders·Vasilios C ConstantinidesElisabeth Kapaki

❮ Previous
Next ❯

Related Concepts

Related Feeds

Alzheimer's Disease: Early Markers

Alzheimer's disease (AD) is a neurodegenerative disease characterized by progressive cognitive and behavioral decline. Targeting markers in the earliest stages of the disease may mitigate the progression of AD. This feed focuses on early diagnosis and markers, as well as environmental, pharmacological, and drug-response biomarkers associated with this disease.

CSF & Lymphatic System

This feed focuses on Cerebral Spinal Fluid (CSF) and the lymphatic system. Discover the latest papers using imaging techniques to track CSF outflow into the lymphatic system in animal models.

Alzheimer's Disease: Amyloid Beta

Alzheimer's disease is a neurodegenerative disease associated with the accumulation of amyloid plaques in the brain; these plaques are comprised of amyloid beta deposits. Here is the latest research in this field.

Alzheimer's Disease: APP

Amyloid precursor protein (APP) proteolysis is critical for the development of Alzheimer's disease, a neurodegenerative disease associated with accumulation of amyloid plaques in the brain. Here is the latest research on APP and Alzheimer's disease.

Alzheimer's Disease: Tau & TDP-43

Alzheimer's disease is a neurodegenerative disease. This feed focuses on the underlying role of tau proteins and TAR DNA-binding protein 43, as well as other genetic factors, in Alzheimer's disease.

ApoE Phenotypes

Apolipoprotein E (APOE) is a protein involved in fat metabolism and associated with the pathogenesis of Alzheimer's disease and cardiovascular disease. Here is the latest research on APOE phenotypes.

© 2022 Meta ULC. All rights reserved